CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Our Holdings

novamentis biotech

Nova Mentis Biotech

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: obesity, diabetes, liver disease (NASH)

Learn More


Pilz BioScience

Pilz Bioscience

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: Autism Spectrum Disorder

Learn More

Nova Mentis Life Science
Stock Performance

CSE FSE

Nova Mentis Autism Clinical Study

 

Sign up to learn more

Latest News

Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference

Vancouver, British Columbia – June 10, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond virtual conference on June 17, 2021.

Nova Mentis Launches Autism Clinical Study

Vancouver, British Columbia – May 6, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that its North American autism clinical study has been listed on ClinicalTrials.gov (NCT04869930), a database of privately and publicly funded clinical studies conducted around the world.